Medical Technology Breaking News:
Aethlon Medical (OTCQB: AEMD) to Present at SeeThruEquity Microcap Investor
Conference
SAN DIEGO - May 26, 2015 (Investorideas.com newswire) Aethlon Medical,
Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic
devices to address infectious diseases and cancer, today announced that James
A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annual
Microcap Investor Conference on Thursday, May 28th. Details of Aethlon
Medical's presentation are as follows:
Event: SeeThruEquity 4th Annual Microcap Investor Conference
Date: Thursday, May 28, 2015
Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time
Location: Convene Grand Central in Midtown Manhattan, New York
Date: Thursday, May 28, 2015
Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time
Location: Convene Grand Central in Midtown Manhattan, New York
A live audio webcast of the presentation will be available on the
Company's website (www.aethlonmedical.com) in the Investor Relations section on
the Events and Presentations or can be accessed directly at http://wsw.com/webcast/seethru11/aemd.
About SeeThruEquity
SeeThruEquity ("STE") is an equity research and corporate
access firm focused on companies with less than $1 billion in market
capitalization. The research is not paid for and unbiased. STE does not conduct
any investment banking or commission based business. STE is approved to
contribute research to Thomson Reuters One (First Call), CapitalIQ, FactSet,
and Zacks, and distribute its research to its database of opt-in investors.
Company research estimates are also contributed to Thomson Estimates, the
leading estimates platform on Wall Street.
About Aethlon Medical, Inc.
Aethlon Medical creates affinity biofiltration devices to treat
life-threatening diseases. Our lead therapeutic candidate is the Aethlon
Hemopurifier®, a first-in-class device that targets the rapid elimination of
infectious viruses and cancer promoting exosomes from the circulatory system of
treated individuals. Our majority owned subsidiary Exosome Sciences, Inc., is
advancing exosome-based liquid biopsies to diagnose and monitor Cancer and
Chronic Traumatic Encephalopathy (CTE), a neurodegenerative disorder often
found in individuals with a history of repetitive brain trauma.
About The Aethlon Hemopurifier®
Of the hundreds of viruses known to be infectious to man, antiviral drug
therapies are approved for fewer than ten. The Aethlon Hemopurifier® provides a
broad-spectrum therapeutic strategy to address drug resistant viral pathogens.
To date, Hemopurifier therapy has been administered to individuals infected
with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human
Immunodeficiency virus (HIV). Time Magazine recently named the Hemopurifier to
their list of 'Top 25 Inventions" and "The 11 Most Remarkable
Advances in Healthcare." Beyond human treatment experiences, pre-clinical
Hemopurifier studies have validated the capture of some of world's deadliest
pathogens. These include: Dengue hemorrhagic fever, Lassa hemorrhagic fever,
H5N1 avian influenza, H1N1 swine flu virus, the reconstructed 1918 influenza
virus, West Nile virus and Vaccinia and Monkeypox, which serve as models for
human smallpox infection. U.S. clinical progression of Hemopurifier therapy is
being advanced under FDA approved clinical studies.
Aethlon is also investigating the use of Hemopurifier therapy to capture
tumor-derived exosomes, a significant unaddressed therapeutic target in cancer
care. Tumor-derived exosomes promote cancer progression through multiple
mechanisms, which include seeding the spread of metastasis and direct
suppression of the immune response. In regards to our therapeutic mechanism of
action, the Hemopurifier incorporates a patented affinity technique that allows
for selective binding to a unique structure that resides on the surface of
tumor-derived exosomes and glycoproteins that coat infectious viruses.
Additional information can be found online at www.AethlonMedical.com or you can
connect with us on on http://www.aethlonmedical.com/and
connect with the Company on Twitter, LinkedIn, Facebook and Google+.
Certain statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, that the ESI will not be able to
commercialize its future products, that the FDA will not approve the initiation
of the Company's clinical programs or provide market clearance of the company's
products, future human studies whether revenue or non-revenue generating of the
Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C therapies
or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense
against viral pathogens, including Ebola, the Company's ability to raise
capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either
internally or through outside companies and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, the ability of the Company to meet the milestones contemplated in
the DARPA contract, product liability exposure, uncertainty of market
acceptance, competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Disclaimer/ Disclosure: Investorideas.com newswire
is a third party publisher of news and research as well as creates original
content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content
publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective
September 15 2008 - all BC investors should review all OTC and Pink sheet
listed companies for adherence in new disclosure filings and filing appropriate
documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment